Hainan Shuangcheng Pharmaceut (SHE:002693) — Market Cap & Net Worth
Market Cap & Net Worth: Hainan Shuangcheng Pharmaceut (002693)
Hainan Shuangcheng Pharmaceut (SHE:002693) has a market capitalization of $529.15 Million (CN¥3.62 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #12076 globally and #3511 in its home market, demonstrating a -4.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hainan Shuangcheng Pharmaceut's stock price CN¥8.72 by its total outstanding shares 414689750 (414.69 Million). Review Hainan Shuangcheng Pharmaceut total liabilities to assess the company's total debt and financial obligations.
Hainan Shuangcheng Pharmaceut Market Cap History: 2015 to 2026
Hainan Shuangcheng Pharmaceut's market capitalization history from 2015 to 2026. Data shows change from $901.13 Million to $529.15 Million (-2.35% CAGR).
Hainan Shuangcheng Pharmaceut Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hainan Shuangcheng Pharmaceut's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.53x
Hainan Shuangcheng Pharmaceut's market cap is 1.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
22.18x
Hainan Shuangcheng Pharmaceut's market cap is 22.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $654.15 Million | $145.14 Million | -$388.41 Million | 4.51x | N/A |
| 2017 | $386.55 Million | $246.77 Million | $6.31 Million | 1.57x | 61.21x |
| 2018 | $236.05 Million | $337.24 Million | -$69.46 Million | 0.70x | N/A |
| 2019 | $282.78 Million | $346.65 Million | $24.66 Million | 0.82x | 11.47x |
| 2020 | $262.75 Million | $269.44 Million | -$53.33 Million | 0.98x | N/A |
| 2021 | $286.42 Million | $320.29 Million | -$20.33 Million | 0.89x | N/A |
| 2022 | $441.16 Million | $274.75 Million | $9.01 Million | 1.61x | 48.95x |
| 2023 | $455.72 Million | $235.93 Million | -$50.74 Million | 1.93x | N/A |
| 2024 | $1.11 Billion | $174.21 Million | -$78.30 Million | 6.38x | N/A |
| 2025 | $422.35 Million | $276.76 Million | $19.04 Million | 1.53x | 22.18x |
Competitor Companies of 002693 by Market Capitalization
Companies near Hainan Shuangcheng Pharmaceut in the global market cap rankings as of June 19, 2026.
Key companies related to Hainan Shuangcheng Pharmaceut by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Hainan Shuangcheng Pharmaceut Historical Marketcap From 2015 to 2026
Between 2015 and today, Hainan Shuangcheng Pharmaceut's market cap moved from $901.13 Million to $ 529.15 Million, with a yearly change of -2.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥529.15 Million | +25.29% |
| 2025 | CN¥422.35 Million | -62.03% |
| 2024 | CN¥1.11 Billion | +144.07% |
| 2023 | CN¥455.72 Million | +3.30% |
| 2022 | CN¥441.16 Million | +54.03% |
| 2021 | CN¥286.42 Million | +9.01% |
| 2020 | CN¥262.75 Million | -7.08% |
| 2019 | CN¥282.78 Million | +19.79% |
| 2018 | CN¥236.05 Million | -38.93% |
| 2017 | CN¥386.55 Million | -40.91% |
| 2016 | CN¥654.15 Million | -27.41% |
| 2015 | CN¥901.13 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Hainan Shuangcheng Pharmaceut was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $529.15 Million USD |
| MoneyControl | $529.15 Million USD |
| MarketWatch | $529.15 Million USD |
| marketcap.company | $529.15 Million USD |
| Reuters | $529.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more